EU approval for first-in-class multiple myeloma drug Farydak

The European Commission has approved Swiss pharma giant Novartis’ (NOVN: VX) Farydak (panobinostat, previously known as LBH589) capsules, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent (IMiD).

The approval of Farydak marks the first time a histone deacetylase (HDAC) inhibitor with epigenetic activity is available in the European Union, providing a new treatment option for patients living with multiple myeloma whose disease has progressed after standard-of-care therapy.

Modest sales forecasts